Nano Pharmaceuticals
Market Cap
₹16 Cr.
P/E
136.27
  • Omkar Pharmachem
  • Norris Medicines
  • Desh Rakshak Aushdh

FAQs on Omkar Pharmachem Ltd. Shareprice

Omkar Pharmachem has given lower returns compared to its competitors.
Omkar Pharmachem has grown at ~-32.31% over the last 4yrs while peers have grown at a median rate of 8.5%

Omkar Pharmachem is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Omkar Pharmachem is 136, while 3 year average PE is 149.
Also latest EV/EBITDA of Omkar Pharmachem is 97.41 while 3yr average is 95.73.

Growth Table

  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Balance Sheet

  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Cash Flow

  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Quarterly Results

  • Omkar Pharmachem Ltd.
  • Norris Medicines
  • Desh Rakshak Aushdh

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Omkar Pharmachem Ltd. Financials

Balance sheet of Omkar Pharmachem is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Omkar Pharmachem is decreasing.
Latest net debt of Omkar Pharmachem is -₹0.22 Crs as of Mar-26.
This is less than Mar-25 when it was -₹0.1 Crs.

The profit is oscillating.
The profit of Omkar Pharmachem is ₹0.2 Crs for Mar 2025, ₹0.19 Crs for Mar 2024 and ₹0.2 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Omkar Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech